Currently, the relationship between high risk Flt3-internal tandem duplications (ITD)+ AML and intermediate risk Flt3-tyrosine kinase domain (TKD) or Flt3-ITD+ Nucleophosmin (NPM1)+ AML has not been clearly established in relation to BH3 mimetic usage. This evidence concerns the gene FLT3 and acute myeloid leukemia.